Table 2.

Modeled projected effectiveness of RV5 against RGE-related hospitalizations in a group of 6 Asian countries: regional projection

	Proportion of total serotypes in 6 Asian countries (A)	Serotype-specific efficacy of RV512 (B)	Attributable effectiveness: Base case scenario† (%)	Attributable effectiveness: Sensitivity analysis§ (%)
G1	0.32	0.95	30	30
G2	0.14	0.88	12	12
G3	0.22	0.93	20	20
G4	0.04	0.89	4	4
G9	0.14	1.0	14	14
G12	0.02	1.0	2	2
M/O/U†,§	0.13	-	7	0
Overall weighted effectiveness in the region			89	82

^†Base case scenario: assumes 50% efficacy against mixed and nontypeable serotypes.

^§Sensitivity analysis: assumes 0% efficacy against mixed and nontypeable serotypes. M/O/U, mixed, other, untypeable; RGE, otavirus gastroenteritis; RV5, oral pentavalent rotavirus vaccine.